Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 3, 2015, Pages 359-369

  Zinzani, P L ^a   Sasse, S ^b   Radford, J ^c   Shonukan, O ^d   Bonthapally, V ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Anaplastic large cell lymphoma; Antibody drug conjugate; Brentuximab vedotin; CD30; Hodgkin lymphoma; Named Patient Program

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPUTER PROGRAM; DIABETES MELLITUS; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GRAFT VERSUS HOST REACTION; HEALTH PROGRAM; HODGKIN DISEASE; HUMAN; INFECTION; INTESTINE OBSTRUCTION; LARGE CELL LYMPHOMA; META ANALYSIS; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SENSORY NEUROPATHY; SEPSIS; SYSTEMATIC REVIEW; T CELL LYMPHOMA; THROMBOCYTOPENIA; LYMPHOMA, LARGE-CELL, ANAPLASTIC; RECURRENT DISEASE;

HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; RECURRENCE;

EID: 84938200077     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.03.011     Document Type: Review

References (30)

1. Francisco J.A., Cerveny C.G., Meyer D.L., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 1024:1458-1465.
2. Wahl A.F., Klussman K., Thompson J.D., et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002, 6213:3736-3742.
3. Doronina S.O., Toki B.E., Torgov M.Y., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 217:778-784.
4. Okeley N.M., Miyamoto J.B., Zhang X., et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010, 163:888-897.
5. Seattle Genetics Inc. ADCETRIS™ (brentuximab vedotin) for injection. Prescribing Information 2012.
6. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 3018:2183-2189.
7. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 3018:2190-2196.
8. Takeda Pharma A/S. ADCETRIS 50mg powder for concentrate for solution for infusion summary of product characteristics 2013, European Medicines Agency (EMA).
9. Zinzani P.L., Viviani S., Anastasia A., et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013, 988:1232-1236.
10. Gibb A., Jones C., Bloor A., et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013, 984:611-614.
11. Rothe A., Sasse S., Goergen H., et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012, 1207:1470-1472.
12. Sasse S., Rothe A., Goergen H., et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2013, 5410:2144-2150.
13. Theurich S., Malcher J., Wennhold K., et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013, 315:e59-e63.
14. Pastorelli F., Derenzini E., Plasmati R., et al. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2013, 5410:2318-2321.
15. Ordemann R., Stohlmacher J., Beuthien-Baumann B., et al. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 2013, 921:125-127.
16. Cao Z.G., Zhou H.W., Peng C.J., et al. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chin J Cancer 2013, 329:520-523.
17. Pellegrini C., Viviani S., Anastasia A., et al. Brentuximab vedotin in 65 relapsed/refractory Hodgkin's lymphoma: preliminary report of a multicenter Italian retrospective study. Haematologica 2012, 97s1(84). abstract 210.
18. Brice P., Monjanel H., Malphettes M., et al. Brentuximab vedotin in heavily treated Hodgkin lymphoma, a retrospective single center study on 30 patients. Haematologica 2012, 97s1:562. abstract 1405.
19. Gibb A., Jones C., Bloor A., et al. Single UK centre experience of brentuximab vedotin monotherapy in refractory CD30+ lymphomas. Haematologica 2012, 97s1:436. abstract 1069.
20. Erdem G., Karadurmus N., Ozaydin S., et al. Brentuximab vedotin (SGN-35) in Hodgkin's lymphoma patients relapsed after autologous peripheral blood stem-cell transplantation. Bone Marrow Transpl 2012, 47s1:S445-S446. abstract P1139.
21. Engels J., Stern M., Bucher C., et al. Serious transplant-related toxicity in patients with Hodgkin's disease previously treated with brentuximab vedotin - a case series. Bone Marrow Transpl 2012, 47s1:S443. abstract P 1132.
22. Theurich S., Malcher J., Wennhold K., et al. Targeted therapy with brentuximab vedotin combined with donor lymphocyte infusions induce sustained clinical remissions and tumor-specific immunity in relapses of Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transpl 2013, 48s2:S72-S458. abstract P816.
23. Rothe A., Sasse S., Goergen H., et al. Brentuximab vedotin (SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation. ASH Annual Meeting Abstracts 2012, 12021. abstract 2743.
24. Theurich S., Malcher J., Wennhold K., et al. CD30-targeted therapy with brentuximab vedotin combined with donor lymphocyte infusions induce sustained clinical remissions and tumor specific immunity in a series of patients with relapsed hodgkin lymphoma after allogeneic stem cell transplantation. ASH Annual Meeting Abstracts 2012, 12021. abstract 4213.
25. Fürst S., Bouabdallah R., Coso D., et al. High response rate and no treatment related mortality after brentuximab vedotin salvage therapy followed by reduced intensity conditioning regimen allogeneic stem cell transplantation (RIC-ALLO) in patients with CD 30+ lymphomas. ASH Annual Meeting Abstracts 2012, 12021. abstract 4526.
26. Monjanel H., Malphettes M., Deville L., et al. Brentuximab vedotin in heavily treated Hodgkin and anaplastic lymphoma, a single center study on 45 patients. Hematol Oncol 2013, 31s1:268. abstract 541.
27. Broccoli A., Derenzini E., Pellegrini C., et al. Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. Clin Lymphoma Myeloma Leuk 2013, 134:493-495.
28. Garciaz S., Coso D., Peyrade F., et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. Hematol Oncol 2013, [Epub ahead of print]. 10.1002/hon.2119.
29. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control 2011, 184:268-276.
30. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 255:579-586.